Get the Stockscreener App
1.57
0.63%
-0.01
After Hours:
1.59
0.02
+1.27%
Aldeyra Therapeutics Inc stock is traded at $1.57, with a volume of 725.00K.
It is down -0.63% in the last 24 hours and down -11.30% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$1.58
Open:
$1.57
24h Volume:
725.00K
Relative Volume:
0.25
Market Cap:
$94.49M
Revenue:
-
Net Income/Loss:
$-33.85M
P/E Ratio:
-2.7847
EPS:
-0.5638
Net Cash Flow:
$-33.35M
1W Performance:
-6.55%
1M Performance:
-11.30%
6M Performance:
-69.46%
1Y Performance:
-43.12%
1-Day Range:
$1.56
$1.62
1-Week Range:
$1.5101
$1.71
52-Week Range:
$1.07
$6.175
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.57 | 95.09M | 0 | -33.85M | -33.35M | -0.5638 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX - ChartMill
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky - Business Wire
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ALDX DEADLINE: The Gross Law Firm Reminds Aldeyra Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline - ChartMill
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - ChartMill
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmALDX - TMX Newsfile
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud - GlobeNewswire
CEO pay, board election and auditor up for Aldeyra (NASDAQ: ALDX) 2026 vote - Stock Titan
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors - GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmALDX - TMX Newsfile
MSN Money - MSN
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra - GlobeNewswire
ALDX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - marketscreener.com
Aldeyra receives FDA rejection for dry eye treatment reproxalap - MSN
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to ... - Bluefield Daily Telegraph
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Coty Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – COTY - GlobeNewswire Inc.
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors with Large ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Encourages Aldeyra - GlobeNewswire
ALDX Shareholder Alert: May 29, 2026 Lead Plaintiff Deadline in Aldeyra Therapeutics, Inc. ... - Bluefield Daily Telegraph
ALDX Forecast, Price Target & Analyst Ratings | ALDEYRA THERAPEUTICS INC (NASDAQ:ALDX) - ChartMill
ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmALDX - TMX Newsfile
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ALDX (Aldeyra Therapeutics Inc.) reports narrower Q4 2025 loss than forecast, topping consensus EPS estimates by 60 percent.Decline Phase - Xã Thanh Hà
ALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors Have - The National Law Review
ALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors Have Until May 29, 2026 To Seek Lead Plaintiff Role - Business Wire
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmALDX - TMX Newsfile
Aldeyra Therapeutics Faces Securities Lawsuit Over Reproxalap Trial Disclosures - TipRanks
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - The Daily Tribune News
2026-04-22 | ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ALDX | Press Release - Stockhouse
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aldeyra - GlobeNewswire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Trip.com Group Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
Aldeyra Therapeutics Announces Upcoming Board Member Departure - The Globe and Mail
FinancialContentINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX - FinancialContent
ALDX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - Finansavisen
ALDX Shareholder Alert: Aldeyra Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm - Morningstar
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Aldeyra Therapeutics director Martin J. Joyce to step down after annual meeting By Investing.com - Investing.com South Africa
Aldeyra Therapeutics director Martin J. Joyce to step down after annual meeting - Investing.com
Martin J. Joyce to Not Seek Re-election to Aldeyra Board - TradingView
Aldeyra Therapeutics (NASDAQ: ALDX) director to exit after 2026 vote - Stock Titan
ADLX Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire
Aldeyra (ALDX) Stock: What Investors Should Know (-1.67%) 2026-04-20Community Momentum Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Aldeyra Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsALDX - Finansavisen
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):